Antisense Therapeutics (ANP) Stock Price, News & Analysis

Company Overview

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.32 million shs
• Average Volume: N/A
• Market Capitalization: A$52.29 million
• P/E Ratio: N/A
• Dividend Yield: 4.58%
• Price Target: N/A
• Consensus Rating: N/A

ANP Stock Analysis - Frequently Asked Questions

How were Antisense Therapeutics' earnings last quarter?

Antisense Therapeutics Limited (ASX:ANP) announced its quarterly earnings results on Wednesday, February, 27th. The company reported $0.00 earnings per share for the quarter. Antisense Therapeutics had a negative net margin of 720.31% and a negative trailing twelve-month return on equity of 73.14%.

What other stocks do shareholders of Antisense Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Antisense Therapeutics investors own include Tocagen (TOCA), Miragen Therapeutics (MGEN), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Iovance Biotherapeutics (IOVA), Genocea Biosciences (GNCA), Capricor Therapeutics (CAPR) and Applied DNA Sciences (APDN).

Company Calendar

• Last Earnings: 2/27/2019
• Today: 7/19/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Consumer Goods
• Current Symbol: ASX:ANP
• CIK: N/A
• Web: www.antisense.com.au
• Phone: 61 3 9827 8999
• Fax: N/A
• Employees: 5,500
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$11.38 million
• Net Margins: -720.31%
• Pretax Margin: N/A
• Return on Equity: -73.14%
• Return on Assets: -41.69%

Debt

• Debt-to-Equity Ratio: 1.42
• Current Ratio: 4.51
• Quick Ratio: 18.16

Sales & Book Value

• Annual Sales: A$1.58 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 4.18
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 901,550,000
• Free Float: N/A
• Market Cap: A$52.29 million
• Optionable: Not Optionable
• Beta: 1.06